newsfilter
← Latest News
Business Wire·

GlycoMimetics Announces Positive Initial Safety and Pharmacokinetic Results from Phase 1a Healthy Volunteer Study of GMI-1687

First in human trial evaluating highly potent E-selectin antagonist, GMI-1687, met its primary and secondary endpoints with no dose-limiting toxicities or safety signals Single ascending dose study confirmed that